MOBI (53) CLPT (19) OFIX (47) TMCI (40) ⌘ Pro Terminal →

Embecta Corp. (EMBC) — RQD Stock Rating Cockpit

$6.56 +1.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.59

Embecta Corp. (EMBC) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (63% profit margin, 36% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →

ROARABLE B • BUY Cap $371.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EMBC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Embecta Corp. (NASDAQ: EMBC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $6.56 (+1.55% 1D, market cap $371.7M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, EMBC ranks #51 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EMBC compare to MOBI and CLPT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), EMBC carries a Roarable B (74/100 RQD), trailing P/E of 3.9x, gross margin of 62.6%, and ROIC of 35.5%. By comparison, MOBI (Mobia Medical Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $375.2M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.7M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EMBC?

▼

Per EMBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001872789), Embecta Corp. generated $1.08B in revenue (-3.8% YoY), $95.4M in net income, and $182.4M in free cash flow against $1.06B in total assets and $1.35B in total debt. Key quantitative strengths: Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.59 (+0.52%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 16.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EMBC)Realized 20D OHLCV Swing Band: ±9.7%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY EMBC SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 16.9% FCF Margin ($182.4M FCF) & 62.6% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$5.99+3.7% Next Q

Q2 (-2Q)

Grade B-$6.21+9.5% Next Q

Q3 (-1Q)

Grade B$6.80-3.5% Next Q

Current

Grade B$6.56+7.3% Hist 90D α

Trajectory: B- (66) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EMBC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, EMBC faces multiple-compression risk if 3.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 60.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.76) or 200D SMA ($6.41) invalidates the momentum regime and cuts Target Base ($7.03) toward Bear Floor ($5.38).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EMBC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EMBC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

58.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE31% OF RANGE

L: $3$6.56H: $15

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (63% profit margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 19 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B-RQD 28 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on EMBC

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (95)

35.5% ROIC with 62.6% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (75)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (67)

28/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like EMBC

✓Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (EMBC Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EMBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.08%⚡ TESTING RESISTANCE

2026-11-02O $6.46H $6.56L $6.46C $6.56VOL 1.11M

RES: $7.11SUP: $3.72SMA50: $5.76SMA200: $6.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EMBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EMBC Butterfly Map → + Track EMBC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. -3.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EMBC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EMBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EMBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EMBC)

Health Care Rank #51 of 1016 ⚔️ MOBI vs EMBC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EMBC vs. MOBI, CLPT, OFIX, TMCI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Embecta Corp. (EMBC) ranks #51 by composite RQD confidence (74/100, grade B) and #489 by equity capitalization ($371.7M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EMBC ACTIVE Embecta Corp.	B	74/100	3.9x	62.6%	35.5%	+1.55%	$371.7M	Benchmark Subject
MOBI Mobia Medical Inc.	D+	53/100	—	—	—	-4.41%	$375.2M	/mobi-vs-embc →
CLPT ClearPoint Neuro Inc.	E	19/100	—	61.4%	-35.0%	+1.23%	$342.7M	/clpt-vs-embc →
OFIX Orthofix Medical Inc.	D	47/100	—	68.8%	-12.2%	+1.99%	$417.1M	/ofix-vs-embc →
TMCI Treace Medical Concepts Inc.	D-	40/100	—	79.8%	-32.4%	+4.76%	$329.1M	/tmci-vs-embc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001872789

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Embecta Corp. (EMBC) reported GAAP revenue of $1.08B (-3.8% vs. FY2024 revenue of $1.12B , and -3.6% cumulative change since FY2023) , GAAP net income of $95.4M, operating cash flow of $191.7M, and free cash flow of $182.4M (+816.6% YoY). On the balance sheet, EMBC closed FY2025 with $1.06B in total assets against $1.35B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$1.08B	$95.4M	$191.7M	$182.4M	$1.06B	$1.35B
FY2024 (FY)	2024-09-30	$1.12B	$78.3M	$35.7M	$19.9M	$1.15B	$1.53B
FY2023 (FY)	2023-09-30	$1.12B	$70.4M	$67.7M	$67.7M	—	—

3. EMBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EMBC compare to MOBI and CLPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EMBC?

Where is EMBC trading relative to its 50-day, 200-day, and 52-week technical levels?

EMBC last traded at $6.56 (+1.55% on volume of 1,108,560 shares), positioning the stock +13.89% above its 50-day simple moving average ($5.76) and +2.34% above its 200-day simple moving average ($6.41). Across its 52-week range of $2.77 to $14.91, EMBC sits at the 31.2% percentile with a 14-day RSI of 58.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.7% ($5.92 to $7.20).

EMBC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EMBC stock right now?

Embecta Corp. (EMBC) currently earns a Roarable Rating of B (Buy — BUY) with 74/100 RQD Confidence. High-quality cash engine (63% profit margin, 36% return on capital) with steady institutional support.

What is EMBC's 12-month price target and RQD AI Jury consensus?

EMBC's 12-month base price target is $7.03 (range $5.38 to $15.66), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EMBC RQD Cockpit EMBC 12M Forecast EMBC Earnings & Move EMBC Dividends & DRIP EMBC Insiders & 13F EMBC Whale Options EMBC Profit Sankey EMBC News & Why